PALVELLA THERAPEUTICS, INC
NASDAQ: PVLA (Palvella Therapeutics, Inc.)
最近更新时间: 昨天, 9:47AM142.85
-2.92 (-2.00%)
新闻情绪
-
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
3天之前, 6:30AM
-
Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
05 Nov, 5:16PM
-
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
05 Nov, 4:14PM
AIStockmoo 评分
| 价值 30% | 0.0 |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | 1.3 |
| 过去一年没有明确趋势。股价略低于52周高点。 参考 | |
| 上升趋势:股价位于均线之上,均线向上。股价接近均线。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 市场情绪 20% | 0.5 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 20% | 1.6 |
| 内部人士没有明显的净买入或净卖出。 参考 | |
| 机构在最新13F申报中净+8.08%的股份:120家增持,80家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+13.5%,回补天数11.5天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利有升有降。近年曾亏损。 参考 | |
| 近期出现看涨反转形态:倒锤子线, 看涨吞没。 参考 | |
| 高于中期趋势线。 参考 | |
| 股价高于其52周平均水平。5年来下跌。 参考 | |
| 短期动能减弱。 参考 | |
| 股价接近支撑位。 参考 | |
| 最终评分 | 0.85 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Palvella Therapeutics, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
| GPCR | 1 B | - | - | 1.01 | -0.8 |
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 11.05% |
| 机构持股比例 | 105.08% |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| MARTINI JEFFREY S | - | 166.33 | -12,500 | -2,079,063 |
| 累积净数量 | -12,500 | |||
| 累积净值 ($) | -2,079,063 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 166.33 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MARTINI JEFFREY S | 职员 | 11 Nov 2026 | 自动卖出 (-) | 6,250 | 163.94 | 1,024,625 |
| MARTINI JEFFREY S | 职员 | 11 Nov 2026 | 执行期权 | 6,250 | - | - |
| MARTINI JEFFREY S | 职员 | 10 Nov 2026 | 自动卖出 (-) | 6,250 | 168.71 | 1,054,438 |
| MARTINI JEFFREY S | 职员 | 10 Nov 2026 | 执行期权 | 6,250 | - | - |
机构
机构持股比例: 103.74%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 120 | 2,170,153 |
| 减持 | 80 | 1,570,653 |
| 新建仓 | 37 | 905,228 |
| 清仓 | 27 | 292,038 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 2,601,661 | 11.5 |
| 15 Oct 2026 | 2,407,482 | 9.8 |
| 30 Sep 2026 | 2,524,140 | 10.7 |
| 15 Sep 2026 | 2,325,699 | 12.8 |
| 31 Aug 2026 | 2,291,288 | 11.1 |
| 14 Aug 2026 | 2,149,544 | 12.8 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 19 Nov 2026 | Yahoo Finance |
Palvella Therapeutics (PVLA) Stock Looks Above Fair Value After 51% Gain
Palvella Therapeutics has logged a strong 51.3% share price gain over the past year, which puts fresh attention on whether that move lines up with what its balance sheet actually supports. With traders also reacting to new product news, the question is how firmly the current valuation rests on… |
| 19 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
EMPD is a serious, rare, and life-threatening genital and perianal skin cancer QTORIN™ docetaxel builds on human clinical evidence of I.V. docetaxel in EMPD, with the potential to shift the treatment paradigm to first-line, localized topical therapy QTORIN™ docetaxel has the potential to be the… |
| 19 Nov 2026 | Yahoo Finance |
Is Palvella Therapeutics (PVLA) Undervalued On Its New QTORIN Webcast Plans?
Palvella Therapeutics (PVLA) is back in focus after the company scheduled a November 19 webcast to introduce a new QTORIN program, the third drug candidate from its QTORIN platform for rare skin conditions. Palvella Therapeutics shares closed at $146.58, with a 1-day share price return of 1.54%.… |
| 18 Nov 2026 | Yahoo Finance |
Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program
Third product candidate from Palvella’s QTORIN™ platform to be announced Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET WAYNE, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a… |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
Palvella Therapeutics Inc (PVLA) advances its Qtorin rapamycin NDA toward a February 2027 PDUFA date while funding a standalone U.S. launch and a deep pipeline of first-in-disease programs. |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Palvella Therapeutics, Inc.'s Q3 2026 earnings call… |
| 05 Nov 2026 | Yahoo Finance |
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential U.S. launch of QTORIN rapamycin after the Food and Drug Administration accepted its application for the treatment of microcystic lymphatic malformations and granted it Priority Review. The FDA set a target action date of February 28,… |
| 05 Nov 2026 | Yahoo Finance |
Palvella (PVLA) Q3 2026 Earnings Call Transcript
QTORIN rapamycin wins priority FDA review for a rare vascular disease. |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics: Q3 Earnings Snapshot
(AP) — Palvella Therapeutics, Inc. (PVLA) on Thursday reported a loss of $24… |
| 05 Nov 2026 | Yahoo Finance |
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 QTORIN™ Rapamycin Could Become the First FDA-Approved Therapy for Microcystic Lymphatic Malformations, a Serious, Rare Lifelong Disease… |
| 03 Nov 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 29 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 28 Oct 2026 | Yahoo Finance |
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and adults in the U.S. Phase 3 SELVA study achieved highly statistically significant results across all… |
| 25 Oct 2026 | Yahoo Finance |
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said during a Chardan investor session. Korenberg said the company has expanded from deve… |
| 24 Oct 2026 | Yahoo Finance |
What Does Palvella Therapeutics (PVLA) NDA Progress Mean After Its Phase 3 Data?
Palvella Therapeutics (NasdaqGM:PVLA) reported positive Phase 3 SELVA trial results for QTORIN rapamycin in microcystic lymphatic malformations. The company has completed an FDA New Drug Application for QTORIN rapamycin following the SELVA efficacy and safety findings. Management also released new… |
| 22 Oct 2026 | Yahoo Finance |
Ligand to Host Investor Day on December 8, 2026
JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY… |
| 21 Oct 2026 | Yahoo Finance |
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering. |
| 15 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in… |
| 13 Oct 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no… |
| 12 Oct 2026 | Yahoo Finance |
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours Comprehensive Real-World… |
| 28 Sep 2026 | Yahoo Finance |
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric… |
| 09 Sep 2026 | Yahoo Finance |
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and… |
| 02 Sep 2026 | Yahoo Finance |
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are… |
| 31 Aug 2026 | Yahoo Finance |
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S. FDA previously granted Breakthrough Therapy and Fast Track… |
| 显示更多 | ||
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合